IL201401A - N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects - Google Patents

N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects

Info

Publication number
IL201401A
IL201401A IL201401A IL20140109A IL201401A IL 201401 A IL201401 A IL 201401A IL 201401 A IL201401 A IL 201401A IL 20140109 A IL20140109 A IL 20140109A IL 201401 A IL201401 A IL 201401A
Authority
IL
Israel
Prior art keywords
oxide
dopamine receptor
cardiovascular side
improved cardiovascular
displaying improved
Prior art date
Application number
IL201401A
Other languages
English (en)
Hebrew (he)
Other versions
IL201401A0 (en
Original Assignee
Ivax Int Gmbh
Nsab Af Neurosearch Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh, Nsab Af Neurosearch Sweden Ab filed Critical Ivax Int Gmbh
Publication of IL201401A0 publication Critical patent/IL201401A0/en
Publication of IL201401A publication Critical patent/IL201401A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL201401A 2007-04-12 2009-10-11 N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects IL201401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700893 2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en) 2007-04-12 2008-04-11 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (2)

Publication Number Publication Date
IL201401A0 IL201401A0 (en) 2010-05-31
IL201401A true IL201401A (en) 2015-10-29

Family

ID=39864178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201401A IL201401A (en) 2007-04-12 2009-10-11 N - Oxide and / or Di - n - Oxides of Dopamine Receptor / modulator Modulators showing enhanced cardiovascular side effects

Country Status (19)

Country Link
US (1) US9139525B2 (enExample)
EP (1) EP2146961B1 (enExample)
JP (1) JP5393654B2 (enExample)
CN (1) CN101711236B (enExample)
AU (1) AU2008239841B2 (enExample)
BR (1) BRPI0810161A2 (enExample)
CA (1) CA2683719C (enExample)
CY (1) CY1115337T1 (enExample)
DK (1) DK2146961T3 (enExample)
ES (1) ES2458592T3 (enExample)
HR (1) HRP20140380T1 (enExample)
IL (1) IL201401A (enExample)
MX (1) MX2009011020A (enExample)
NZ (1) NZ580856A (enExample)
PL (1) PL2146961T3 (enExample)
PT (1) PT2146961E (enExample)
RU (1) RU2470013C2 (enExample)
SI (1) SI2146961T1 (enExample)
WO (1) WO2008127188A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US8673962B2 (en) 2008-11-24 2014-03-18 Integrative Research Laboratories Sweden Ab 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
AU2012306386B2 (en) 2011-09-07 2017-06-15 Teva Pharmaceuticals International Gmbh Polymorphic form of pridopidine hydrochloride
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
ES2879631T3 (es) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de la enfermedad de Huntington
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
IL268125B2 (en) 2017-01-20 2023-04-01 Prilenia Neurotherapeutics Ltd Pridopidine for the treatment of fragile x syndrome
PT4154882T (pt) 2017-08-14 2025-11-19 Prilenia Neurotherapeutics Ltd Tratamento da esclerose lateral amiotrófica com pridopidina
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1217296A (en) 1917-01-11 1917-02-27 Lewis A Peckham Shock-absorber.
US2813097A (en) 1955-08-16 1957-11-12 Upjohn Co 3-hydroxy-n-methylmorphinan-n-oxide
US2813098A (en) 1955-08-16 1957-11-12 Upjohn Co 3-methoxy-n-methylmorphinan n-oxide
US3131185A (en) 1959-03-18 1964-04-28 Orsymonde Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (enExample) 1962-10-10
CH481124A (de) 1966-09-21 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
AU653837B2 (en) 1991-04-17 1994-10-13 Pharmacia & Upjohn Company Substituted phenylazacycloalkanes as CNS agents
WO1993000313A2 (en) 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ATE253364T1 (de) * 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
JP2008501749A (ja) 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
MXPA06013944A (es) * 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
AU2005273961A1 (en) * 2004-08-11 2006-02-23 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
CN101056854B (zh) * 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
PL1919883T3 (pl) 2005-08-22 2009-06-30 Solvay Pharm Bv N-TLENKI JAKO PROLEKI PIPERAZYNOWYCH oraz PIPERYDYNOWYCH POCHODNYCH
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
MX2008013887A (es) * 2006-05-02 2009-01-29 Solvay Pharm Bv N-oxidos de derivados de piridilmetilpiperazina y piridilmetilpiperdina.
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2011107593A1 (en) * 2010-03-05 2011-09-09 Dsm Ip Assets B.V. Process for the production of an uhmwpe article
WO2012028635A1 (en) * 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
AU2012306386B2 (en) 2011-09-07 2017-06-15 Teva Pharmaceuticals International Gmbh Polymorphic form of pridopidine hydrochloride
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
EP2844346B1 (en) * 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EP2900226A4 (en) * 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
EA201590655A8 (ru) * 2012-09-27 2016-07-29 Тева Фармасьютикал Индастриз Лтд. Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений

Also Published As

Publication number Publication date
ES2458592T3 (es) 2014-05-06
WO2008127188A1 (en) 2008-10-23
MX2009011020A (es) 2009-10-30
PL2146961T3 (pl) 2014-09-30
CN101711236B (zh) 2012-10-31
BRPI0810161A2 (pt) 2014-12-30
CY1115337T1 (el) 2017-01-04
CN101711236A (zh) 2010-05-19
JP2010523651A (ja) 2010-07-15
US20100105736A1 (en) 2010-04-29
IL201401A0 (en) 2010-05-31
CA2683719A1 (en) 2008-10-23
AU2008239841A1 (en) 2008-10-23
EP2146961A4 (en) 2011-08-03
US9139525B2 (en) 2015-09-22
RU2009141300A (ru) 2011-05-20
CA2683719C (en) 2015-07-14
PT2146961E (pt) 2014-04-30
EP2146961B1 (en) 2014-01-29
SI2146961T1 (sl) 2014-08-29
DK2146961T3 (da) 2014-04-28
NZ580856A (en) 2011-11-25
HRP20140380T1 (hr) 2014-08-15
RU2470013C2 (ru) 2012-12-20
JP5393654B2 (ja) 2014-01-22
AU2008239841B2 (en) 2013-07-18
EP2146961A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
IL201401A0 (en) N - oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
IL201202A0 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
IL210412A0 (en) Heterocyclic derivatives and uses thereof
EP2265731A4 (en) METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE
ZA201008611B (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
EP2188295A4 (en) PYRIDINE DERIVATIVES AND METHODS OF USE
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
IL206276A0 (en) Pyridine derivatives
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL206225A0 (en) Compositions and methods of detecting tiabs
SI2615085T1 (sl) Piridilni derivati kot cftr-modulatorji
IL208203A0 (en) Heterocyclic derivatives
SI2110502T1 (sl) Skriti šarnir
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
BRPI0919331A2 (pt) derivados de pirazolo piridina, composições farmacêuticas e métodos associados
IL212636A0 (en) Pyridazinone derivatives
IL213570A (en) History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them
EP2081950A4 (en) EXPRESSION PROFILES ASSOCIATED WITH IRINOTECAN TREATMENT
IL213352A0 (en) Dihydropyridone amides as p2x7 modulators
EP2139891A4 (en) 4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE
IL213417A0 (en) Dihydropyridone amides as p2x7 modulators
EP2285778A4 (en) NIKOTINAMIDDERIVATE
EP2204398A4 (en) CAMPTOTHECIN POLYMER DERIVATIVE AND USES THEREOF
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees